E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult Patients with Persistent Allergic Asthma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001705 |
E.1.2 | Term | Allergic asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this clinical Phase IIa trial is to assess the pharmacodynamic and clinical efficacy of QbG10 as disease modifying drug administered to patients with persistent allergic asthma. Furthermore, safety, tolerability and immunogenicity of QbG10 will be assessed. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Able and willing to provide written informed consent • Able and willing to complete all protocol requirements • 18 to 65 years of age • History of persistent asthma according to GINA 2007 guidelines whose symptoms requiring long-term treatment with ICS • Positive skin prick test to at least one aero-allergen and anamnestically confirmed to cause asthma symptoms. In case of doubt the allergic nature of the asthma must be confirmed by nasal provocation with the suspected allergen. • FEV1 >60% of predicted value • FEV1 improvement >=12% after inhaled beta2-agonist (400 µg salbutamol) at screening • Airway responsiveness to methacholine (PC20 <8 mg/mL) at screening (prior to run-in phase) • On stable therapy with ICS equivalent to a dose of ≥500 µg BDP daily (short-acting beta2-agonists (salbutamol) as needed may be used throughout the whole study) • Clinically stable asthma or sufficiently controlled asthma at screening and prior to treatment phase as indicated by <1.5 mean points in the Asthma Control Questionnaire (ACQ) • Female participants must meet one of the following criteria: - No reproductive potential due to menopause (one year without menses, in case of doubts serum FSH will be determined and must be >30 U/mL and estradiol must be <54.7pg/mL), hysterectomy, bilateral oophorectomy, or tubal ligation - Patient agrees to consistently practice an effective and accepted method of contraception throughout the duration of the study and for 1 additional month after the last immunization (hormone-based, or intrauterine device, or double barrier contraception, i.e. condom + diaphragm, condom or diaphragm + spermicidal gel or foam)
|
|
E.4 | Principal exclusion criteria |
• Use of oral corticosteroids within past 3 months • Hospitalization for asthma exacerbation within past 6 months • Uncontrolled asthma defined by ACQ ≥1.5 points at screening or prior to treatment phase • Intermittent or seasonal asthma not requiring ICS treatment • Regular use of long-acting beta2-agonists (LABA). All LABAs should be discontinued after informed consent and at least 48h prior to the screening procedure to ensure appropriate washout. • Smokers or quitters with a smoking history of >10 packyears (one package per day for 10 years) •Major surgery within 4 weeks prior to enrollment • Presence or history of relevant cardiovascular, renal, pulmonary, endocrine, autoimmune, dermatological (in particular psoriasis), neurological and psychiatric (in particular depression) and ocular disease (in particular keratitis) as judged by the investigator. For psoriasis, family history should also be clean. • Current diagnosis or history of malignancy; presence of suspicious lymphadenopathy or splenomegaly on physical examination • Confirmed or suspected current infection with HIV, HBV, or HCV • Presence of active infectious disease as judged by the investigator • History of recurrent invasive streptococcal or staphylococcal infections, or known interleukin-1 receptor-associated kinase 4 (IRAK 4) deficiency • Active autoimmune diseases • Pregnancy (based on positive urine test at screening visit) or lactation • Female planning to become pregnant during the study period • Blood donation or loss of > 400 mL within 8 weeks prior to inclusion • Vaccination planned during study treatment period • History of abuse of alcohol or other recreational drugs • Lactose intolerance • Any specific immunotherapy (SIT) planned during the whole study period or any former SIT within the last three years. • Treatment with anti-IgE antibodies within past 6 months • Use of any investigational drug within 30 days before enrolment, or planned use during the whole study period • Previous participation in a clinical trial with a Qb-based vaccine • Possible dependency of the patient on sponsor and/or investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Inflammatory parameters (NO in exhaled air;Eosinophils in peripheral blood) and Clinical parameters (Methacholine test; Asthma questionnaire; Daytime/nighttime symptoms; Morning PEF; Use of rescue medication; Tolerance of ICS dose reduction; Skin prick test) serve as endpoints.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |